The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 with ECOG PS ≤ 2 and between 71 and 75 with ECOG PS = 0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender.

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Marmorino, F;Rossini, D;Moretto, R;Zucchelli, G;Masi, G;Borelli, B;Boccaccino, A;Falcone, A;Cremolini, C
2019-01-01

Abstract

The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 with ECOG PS ≤ 2 and between 71 and 75 with ECOG PS = 0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender.
Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A; Latiano, T P; Cordio, S; Passardi, A; Tamburini, E; Boni, L; Falcone, A; Cremolini, C
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1019319
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact